![]() ![]() ![]() The groups which claim for the view of MDS-MSCs are normal, have shown that the cellular morphology, expression of surface antigens, and differentiation ability of MDS-MSCs are comparable to normal MSCs, and are devoid of chromosomal aberrations. While some reports have found that the stromal compartment in MDS is cytogenetically and functionally normal, other researches have shown that the MSCs are cytogenetically abnormal and defective in carrying out their normal functions. Functional integrity of BM-MSCs in MDS and their contribution in pathogenesis and progression of MDS are controversial. Emerging research and in vitro models demonstrate that the disease is not simply derived from an abnormal HSC clone but also is a combined result of defective cells in the marrow microenvironment and their complex interactions with hematopoietic compartment. Myelodysplastic Syndromes (MDS) are a complex bone marrow hematopoietic stem cell disorders characterized by peripheral cytopenia, cellular dysplasia, and dysfunction resulting in an ineffective hematopoiesis. Biological characteristics of MSCs, the most vital component in the functioning niche for HSCs, are thought to be altered in hematological malignancies. Bone marrow (BM) resident MSCs regulate hematopoiesis, homeostasis, and maintenance of hematopoietic stem cells (HSCs) through direct cell to cell contacts and by secretion of regulatory factors. They are characterized by the expression of CD73, CD90, and CD105 and lack expression of hematopoietic markers such as CD34 and CD45. Multipotent mesenchymal stem/stromal cells (MSCs) are a group of undifferentiated cells, with the ability of self-renewal and differentiation into multiple cell lineages including adipocytes, osteocytes, and chondrocytes. Further, the occurrence of genetic abnormalities in BM-MSCs in MDS could be considered as an autonomous event from that of their hematopoietic counterparts. Results show that in spite of presence of genetically abnormal clones in MDS-MSC populations, in vitro phenotypic and growth characteristics of MSCs in MDS remain unchanged. Patients with abnormal BM karyotypes had no aberrant MSC clones. Highest percentage of karyotypic abnormalities was observed in RCMD-MSCs. 31% of MDS-MSCs had chromosomal aberrations (der(3),del(6q),del(7p), loss of chromosomes) whose BM karyotypes were normal. ![]() No significant growth differences were observed between control MSCs and MDS-MSCs of all subtypes ( p > 0.05). Cell morphology, differentiation potential, and CD marker expression of MDS-MSCs of all subtypes were comparable to those of control-MSCs. Karyotyping and FISH were performed on MSCs. Growth properties were determined using growth curves and population doubling times. MSCs were culture-expanded, characterized by flow cytometry, and induced towards osteogenic and adipogenic differentiation. We also analyzed MSCs derived from different MDS subtypes. We characterized MSCs of de novo MDS patients in Sri Lanka who have not been reported previously in the literature. Whether BM-MSCs alter their characteristics in Myelodysplastic Syndromes (MDS) is still controversial. Bone marrow (BM) mesenchymal stem/stromal cells (MSCs) are vital in hematopoiesis. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |